<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01124344</url>
  </required_header>
  <id_info>
    <org_study_id>CN166-002</org_study_id>
    <secondary_id>2010-018461-38</secondary_id>
    <nct_id>NCT01124344</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacology Study of BMS-866949</brief_title>
  <official_title>Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-866949 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine whether multiple doses.of BMS-886949 are safe
      and tolerable
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of safety by evaluating incidence of adverse events (AE)</measure>
    <time_frame>Over a period of 28 days (+/- 2 days) of first dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetics by evaluating plasma concentration versus time data</measure>
    <time_frame>Over a period 28 days (+/- 2 days) of first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacodynamics by evaluating brain transporter occupancy</measure>
    <time_frame>Over a period 28 days (+/- 2 days) of first dose</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Major Depression</condition>
  <arm_group>
    <arm_group_label>Placebo or BMS-866949 (3 mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Panel 1: Healthy Male Subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo or BMS-866949 (10 mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Panel 2: Healthy Male Subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo or BMS-866949 (30 mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Panel 3: Healthy Male Subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo or BMS-866949 (45 mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Panel 4: Healthy Male Subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo or BMS-866949 (60 mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Panel 5: Healthy Male Subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo or BMS-866949 (90 mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Panel 6: Healthy Male Subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo or BMS-866949 (3 - 60 mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Panel 7: Females</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral Solution, Oral, 0 mg, Once Daily, 14 days</description>
    <arm_group_label>Placebo or BMS-866949 (3 mg)</arm_group_label>
    <arm_group_label>Placebo or BMS-866949 (10 mg)</arm_group_label>
    <arm_group_label>Placebo or BMS-866949 (30 mg)</arm_group_label>
    <arm_group_label>Placebo or BMS-866949 (45 mg)</arm_group_label>
    <arm_group_label>Placebo or BMS-866949 (60 mg)</arm_group_label>
    <arm_group_label>Placebo or BMS-866949 (90 mg)</arm_group_label>
    <arm_group_label>Placebo or BMS-866949 (3 - 60 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-866949</intervention_name>
    <description>Oral Solution, Oral, 3 mg, Once Daily, 14 days</description>
    <arm_group_label>Placebo or BMS-866949 (3 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-866949</intervention_name>
    <description>Oral Solution, Oral, 10 mg, Once Daily, 14 days</description>
    <arm_group_label>Placebo or BMS-866949 (10 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-866949</intervention_name>
    <description>Oral Solution, Oral, 30 mg, Once Daily, 14 days</description>
    <arm_group_label>Placebo or BMS-866949 (30 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-866949</intervention_name>
    <description>Oral Solution, Oral, 45 mg, Once Daily, 14 days</description>
    <arm_group_label>Placebo or BMS-866949 (45 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-866949</intervention_name>
    <description>Oral Solution, Oral, 60 mg, Once Daily, 14 days</description>
    <arm_group_label>Placebo or BMS-866949 (60 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-866949</intervention_name>
    <description>Oral Solution, Oral, 90 mg, Once Daily, 14 days</description>
    <arm_group_label>Placebo or BMS-866949 (90 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-866949</intervention_name>
    <description>Oral Solution, Oral, 3-60 mg, Once Daily, 14 days</description>
    <arm_group_label>Placebo or BMS-866949 (3 - 60 mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Panels 1-6: Healthy Male Subjects

          -  Panel 7: Females

          -  Ages 21 to 55, inclusive

          -  Body Mass Index (BMI) of 18 to 32 kg/mÂ², inclusive

          -  Healthy subjects as determined by no clinically significant deviation from normal in
             medical history, physical examination, ECGs, and clinical laboratory determinations

        Exclusion Criteria:

          -  History of glaucoma or a confirmed intraocular pressure indicative of glaucoma at
             screening. (Normal IOP &lt;21 mmHg)

          -  History or family history of psychiatric disorder

          -  Current treatment with prescription medication

          -  Exposure to any investigational drug or placebo within 12 weeks of study drug
             administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Uppsala</city>
        <zip>751 23</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2010</study_first_submitted>
  <study_first_submitted_qc>May 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2010</study_first_posted>
  <last_update_submitted>March 26, 2012</last_update_submitted>
  <last_update_submitted_qc>March 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

